A prospective, single-arm, phase II trial of Tislelizumab plus donafenib combined with transarterial chemoembolization in patients with resected high-risk hepatocellular carcinoma (TIDE)
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Donafenib (Primary) ; Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms TIDE
- 20 Jan 2025 New trial record